PODD logo

Insulet Corporation (PODD)

$143.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PODD

Market cap

$9.93B

EPS

4.28

P/E ratio

33.2

Price to sales

3.4

Dividend yield

--

Beta

1.125522

Price on PODD

Previous close

$142.43

Today's open

$144.47

Day's range

$141.45 - $145.34

52 week range

$140.63 - $354.88

Profile about PODD

CEO

Ashley McEvoy

Employees

5400

Headquarters

Acton, MA

Exchange

Nasdaq Global Select

Shares outstanding

69264674

Issue type

Common Stock

PODD industries and sectors

Healthcare

Medical Equipment & Supplies

News on PODD

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

news source

Business Wire • 8 hours ago

news preview

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

news source

Seeking Alpha • a day ago

news preview

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

news source

Business Wire • Jun 3, 2026

news preview

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

news source

Zacks Investment Research • Jun 2, 2026

news preview

US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.

news source

Reuters • May 28, 2026

news preview

PODD Stock: What a Hold Rating Says at a $163 Target

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

news source

Zacks Investment Research • May 28, 2026

news preview

PODD and Omnipod 5: What's Driving Insulet's 2026 Growth

Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

news source

Zacks Investment Research • May 27, 2026

news preview

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insul.

news source

Business Wire • May 27, 2026

news preview

Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost

Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across ​its Omnipod product lines after identifying a manufacturing ‌issue that could result in patients receiving too little insulin.

news source

Reuters • May 26, 2026

news preview

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omn.

news source

Business Wire • May 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Insulet Corporation

Open an M1 investment account to buy and sell Insulet Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PODD on M1